)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
AN2 Therapeutics (ANTX) investor relations material
AN2 Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Advanced boron-based therapeutics for Chagas disease, melioidosis, NTM lung disease, oncology, and infectious diseases, with multiple programs in clinical and preclinical stages.
Initiated Phase 1 trial for Chagas disease (AN2-502998), completed first cohort dosing, and formed a collaboration with DNDi to accelerate Phase 2 planning.
Completed a 200-patient melioidosis study, revealing high mortality and biothreat potential; planning for Phase 2 with ongoing government funding discussions.
Announced a 50% workforce reduction in August 2024 to extend capital after EBO-301 study discontinuation.
No products approved or revenue generated; operations funded by equity offerings, grants, and collaborations.
Financial highlights
Net loss of $6.5 million for Q2 2025, down from $14.4 million in Q2 2024; R&D expenses decreased 74% year-over-year to $3.2 million.
General and administrative expenses rose to $4.0 million in Q2 2025, mainly from higher professional services.
Interest income declined to $0.8 million in Q2 2025 from $1.4 million in Q2 2024 due to lower cash balances and rates.
Cash, cash equivalents, and investments totaled $71.2 million as of June 30, 2025.
Net cash used in operating activities was $18.2 million for H1 2025, down from $32.0 million in H1 2024.
Outlook and guidance
Cash runway projected to fund operations for at least 12 months, potentially into 2028 under the current plan.
Plans to complete Phase 1 dosing for AN2-502998 in H2 2025 and initiate Phase 2 in 2026; first oncology compound to enter development in 2025.
Ongoing efforts to secure non-dilutive government and foundation funding for clinical programs.
Anticipates increased operating expenses as pipeline advances, with continued need for additional capital.
How does DNDI collaboration preserve capital?
Update on US government funding for melioidosis?
Timeline for oncology development candidates?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AN2 Therapeutics earnings date
Q3 202512 Nov, 2025
Next AN2 Therapeutics earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
AN2 Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases. The company specializes in novel small-molecule therapies designed to address unmet medical needs, particularly in non-tuberculous mycobacterial (NTM) lung disease and other bacterial infections. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage